Tag: GLP1

GLP-1 drugs may be linked to higher risk of eye disease: study

A recent observational study published in JAMA Ophthalmology has found a potential link between the use of GLP-1

‘Ozempic Teeth’, ‘Tongue’, ‘Breath’ As Possible GLP-1 Med Oral Effects

But GLP-1 receptors are also found in other places, including your tongue. So, it’s not a stretch to

Hype Or Hope? Latest Research On GLP-1 Receptor Agonists And Addiction

It seems that the focus has primarily been on nicotine and alcohol thus far. However, the potential for

‘Ozempic Mouth,’ ‘Feet’ Are Latest Names For GLP-1 Med Side Effects

One personal trainer, Mike Kimani, has begun offering specific workout regimens for clients like Jessica Bunge, who are

Humana’s CenterWell Expands Specialty Pharmacy As GLP-1 Drugs Take Off

Humana’s CenterWell healthcare services business has announced its expansion into the direct-to-patient specialty pharmacy sector, marking a significant

Janelle Rohner Refunds Fans Amid GLP-1 Medication Backlash

Janelle Rohner, a well-known wellness influencer, recently faced backlash after admitting to using a GLP-1 medication to aid

Janelle Rohner Explains Her Controversial GLP-1 Weight Loss Journey

Health and wellness influencer Janelle Rohner recently made a candid revelation on her YouTube channel, sharing her journey

Why GLP-1 Weight-Loss Drugs Are Hard to Make into Pills

The popularity of Ozempic shots, also known as GLP-1 receptor agonists, has soared due to their effectiveness in

How GLP-1 Policy Fits Into Trump’s Greenland Strategy, And 5 Other Health Tech Developments

How does this impact patient care and the trust between patients and their healthcare providers? AI in healthcare

GLP-1 drugs carry wide variety of risks, benefits beyond weight loss

GLP-1 drugs like Ozempic have become incredibly popular for their effectiveness in treating diabetes and promoting weight loss.

GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet

This trend of non-persistence with weight loss drugs adds another layer of complexity to the cost-effectiveness of GLP-1

U.S. adult obesity rate fell in 2023, as use of GLP-1 meds rose

The findings showed that the obesity rate in the United States decreased from 46.2% in 2021 to 45.6%